Sun pharma, India’s most valuable generic drug manufacturing firm, is looking to expand its horizon to cover China and Japan. 35% of the company’s over Rs. 30,000 crore revenue comes from the US market. However, the company is facing the heat from the competition and its operating margin have come under pressure.

Markets like China and Japan have been witnessing keen interest from domestic companies in recent times for growth. In such a scenario, Sun Pharma is looking to partner with leading pharma companies in China to introduce its specialty, differentiated and generic products. The company has already had an experience of partnering with China Medical System Holdings for both its specialty and generic products.

Japan is world’s second largest pharmaceutical market. It gives Sun Pharma a huge market base in branded segment. With the company having a good number of branded specialty products in its kitty, entering the Japan with strong front-end and manufacturing capabilities, can be lucrative for the company.